Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CG Oncology Inc. (CGON)
USD71.74
-0.76 (-1.05%)
US NASDAQ Healthcare Biotechnology
Address
400 Spectrum Center Drive 92618
Irvine, CA, US
Irvine, CA, US
CEO
Arthur Kuan
Website
cgoncology.com
IPO
2024-01-25
CIK 1991792 ISIN US1569441009
Description
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD71.74
-0.76 (-1.05%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.31
Float Shares
56.01M
Free Float %
66.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.43% | +1.70% | +2.39% | +34.29% | +75.89% | +66.96% | +175.52% | +86.49% | +86.49% | +86.49% | +86.49% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
71.74
Low
70.00
-2.4%
Consensus
81.57
+13.7%
Median
81.00
+12.9%
High
93.00
+29.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 11 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
79.00
+10.1%
|
| Last Quarter | 2 |
84.50
+17.8%
|
| Last Year | 15 |
75.60
+5.4%
|
| All Time | 20 |
71.30
-0.6%
|
Quality scores
Altman Z-Score
81.12
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+254.7% ★ Q1'26: +1,982.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-47.5% Q1'26: -57.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,896.2% Q1'26: -5,286.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-3,985.0% Q1'26: -6,130.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-921.7% Q1'26: -1,149.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+23.7% Q1'26: +10.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 9 EPS Ana. |
Dec 2027 11 Rev. Ana. 10 EPS Ana. |
Dec 2028 12 Rev. Ana. 11 EPS Ana. |
Dec 2029 11 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
204.0K
est: 100.8K (+102.5%)
|
1.14M
est: 1.28M (-11.0%)
|
4.04M
est: 2.81M (+43.5%)
|
13.74M
2.11M – 36.97M
+388.1% YoY
|
95.57M
63.10M – 146.69M
+595.6% YoY
|
452.18M
450.27M – 454.09M
+373.1% YoY
|
905.76M
371.32M – 1.54B
+100.3% YoY
|
1.45B
593.91M – 2.46B
+59.9% YoY
|
| EBITDA |
-55.43M
est: -100.8K (-54,919.4%)
|
-114.63M
est: -1.28M (-8,852.7%)
|
-159.55M
est: -2.81M (-5,568.1%)
|
-13.74M
-36.97M – -2.11M
-388.1% YoY
|
-95.57M
-146.69M – -63.10M
-595.6% YoY
|
-452.18M
-454.09M – -450.27M
-373.1% YoY
|
-905.76M
-1.54B – -371.32M
-100.3% YoY
|
-1.45B
-2.46B – -593.91M
-59.9% YoY
|
| EBIT |
-55.45M
est: -100.8K (-54,936.2%)
|
-114.67M
est: -1.28M (-8,855.2%)
|
-161.00M
est: -2.81M (-5,619.5%)
|
-13.74M
-36.97M – -2.11M
-388.1% YoY
|
-95.57M
-146.69M – -63.10M
-595.6% YoY
|
-452.18M
-454.09M – -450.27M
-373.1% YoY
|
-905.76M
-1.54B – -371.32M
-100.3% YoY
|
-1.45B
-2.46B – -593.91M
-59.9% YoY
|
| Net Income |
-48.61M
est: -83.28M (+41.6%)
|
-88.04M
est: -99.20M (+11.3%)
|
-161.00M
est: -168.97M (+4.7%)
|
-223.82M
-257.99M – -173.87M
-32.5% YoY
|
-241.14M
-338.72M – -26.86M
-7.7% YoY
|
-28.65M
-129.22M – 134.08M
+88.1% YoY
|
236.26M
55.03M – 451.11M
+924.6% YoY
|
495.52M
115.42M – 946.14M
+109.7% YoY
|
| SGA |
9.90M
est: 2.82M (+250.8%)
|
33.70M
est: 33.35M (+1.0%)
|
73.53M
est: 73.32M (+0.3%)
|
357.91M
54.96M – 963.12M
+388.1% YoY
|
2.49B
1.64B – 3.82B
+595.6% YoY
|
11.78B
11.73B – 11.83B
+373.1% YoY
|
23.59B
9.67B – 40.10B
+100.3% YoY
|
37.74B
15.47B – 64.14B
+59.9% YoY
|
| EPS |
-1.02
est: -1.33 (+23.5%)
|
-1.41
est: -1.27 (-10.7%)
|
-2.08
est: -2.18 (+4.4%)
|
-2.65
-3.34 – -2.25
-21.9% YoY
|
-2.70
-4.38 – -0.35
-1.9% YoY
|
-0.25
-1.67 – 1.73
+90.7% YoY
|
3.06
0.71 – 5.84
+1,313.4% YoY
|
6.41
1.49 – 12.24
+109.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | RBC Capital | Outperform | Outperform | Maintain |
| 2026-04-17 | JP Morgan | Overweight | Overweight | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-154.57M
OE per share TTM
-1.95
Owner's Yield
-2.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
133.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
88
Total invested
816.16M
Insider transactions (90d)
1
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SONG, Hong Fang | 5.56M | 8.30% | 5.56M | — | 5.56M | — | IN | British Virgin Islands | 2024-07-22 | ↗ |
| 2 | Xiangmin Cui | 5.06M | 7.60% | — | 5.06M | — | — | IN | United States | 2024-02-08 | ↗ |
| 3 | Healthcare Seed Limited | 4.94M | 7.40% | 4.94M | — | 4.94M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 4 | Juliet Tammenoms Bakker | 4.66M | 7.00% | — | 4.66M | — | 4.66M | IN | Delaware | 2024-02-05 | ↗ |
| 5 | Patrick G. Enright | 4.66M | 7.00% | — | 4.66M | — | 4.66M | IN | Delaware | 2024-02-05 | ↗ |
| 6 | Decheng Capital Global Life Sciences Fund IV, L.P. | 4.56M | 6.90% | — | 4.56M | — | — | PN | Cayman Islands | 2024-02-08 | ↗ |
| 7 | Decheng Capital Management IV (Cayman), LLC | 4.56M | 6.90% | — | 4.56M | — | — | OO | Cayman Islands | 2024-02-08 | ↗ |
| 8 | Charming Jade Limited | 3.93M | 5.90% | 3.93M | — | 3.93M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 9 | ORI Capital II Inc. | 3.93M | 5.90% | 3.93M | — | 3.93M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 10 | ORI Healthcare Fund II, L.P. | 3.93M | 5.90% | 3.93M | — | 3.93M | — | PN | British Virgin Islands | 2024-07-22 | ↗ |
| 11 | ORI Holding II Inc. | 3.93M | 5.90% | 3.93M | — | 3.93M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 12 | S James Tananbaum (“Tananbaum”) | 3.60M | 5.70% | 3.60M | — | 3.60M | — | IN | Delaware | 2024-02-05 | ↗ |
| 13 | (1) BlackRock, Inc. | 3.57M | 5.30% | 3.52M | — | — | — | HC | Delaware | 2024-11-08 | ↗ |
| 14 | Chen Yu | 3.57M | 5.40% | — | 3.57M | — | 3.57M | IN | — | 2024-02-09 | ↗ |
| 15 | TCG Crossover Fund I, L.P. | 3.57M | 5.40% | — | 3.57M | — | 3.57M | PN | — | 2024-02-09 | ↗ |
| 16 | TCG Crossover GP I, LLC | 3.57M | 5.40% | — | 3.57M | — | 3.57M | OO | — | 2024-02-09 | ↗ |
| 17 | Kissei Pharmaceutical Co., Ltd. | 3.54M | 5.30% | 3.54M | — | 3.54M | — | CO | Nagano, Japan | 2024-03-14 | ↗ |
| 18 | Longitude Capital Partners IV, LLC | 3.19M | 4.80% | — | 3.19M | — | 3.19M | OO | Delaware | 2024-02-05 | ↗ |
| 19 | Longitude Venture Partners IV, L.P. | 3.19M | 4.80% | — | 3.19M | — | 3.19M | PN | Delaware | 2024-02-05 | ↗ |
| 20 | S Foresite Capital Fund VI, L.P. (“FCF VI”) | 2.05M | 3.20% | 2.05M | — | 2.05M | — | PN | Delaware | 2024-02-05 | ↗ |
| 21 | S Foresite Capital Management VI, LLC (“FCM VI”) | 2.05M | 3.20% | 2.05M | — | 2.05M | — | OO | Delaware | 2024-02-05 | ↗ |
| 22 | Longitude Prime Fund, L.P. | 1.47M | 2.20% | — | 1.47M | — | 1.47M | PN | Delaware | 2024-02-05 | ↗ |
| 23 | Longitude Prime Partners, LLC | 1.47M | 2.20% | — | 1.47M | — | 1.47M | OO | Delaware | 2024-02-05 | ↗ |
| 24 | ORI Capital Holding Inc. | 1.01M | 1.50% | 1.01M | — | 1.01M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 25 | ORI Capital Inc. | 1.01M | 1.50% | 1.01M | — | 1.01M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 26 | ORI Healthcare Fund, L.P. | 1.01M | 1.50% | 1.01M | — | 1.01M | — | PN | British Virgin Islands | 2024-07-22 | ↗ |
| 27 | Unique Diamond Investments Limited | 1.01M | 1.50% | 1.01M | — | 1.01M | — | CO | British Virgin Islands | 2024-07-22 | ↗ |
| 28 | Foresite Capital Opportunity Management V, LLC (“FCM Opp V”) | 857.6K | 1.40% | 857.6K | — | 857.6K | — | OO | Delaware | 2024-02-05 | ↗ |
| 29 | Opp V”) | 857.6K | 1.40% | 857.6K | — | 857.6K | — | PN | Delaware | 2024-02-05 | ↗ |
| 30 | Foresite Capital Fund V, L.P. (“FCF V”) | 692.6K | 1.10% | 692.6K | — | 692.6K | — | PN | Delaware | 2024-02-05 | ↗ |
| 31 | S Foresite Capital Management V, LLC (“FCM V”) | 692.6K | 1.10% | 692.6K | — | 692.6K | — | OO | Delaware | 2024-02-05 | ↗ |
| 32 | Decheng Capital Global Healthcare Fund (Master), LP | 500.0K | 0.80% | — | 500.0K | — | — | PN | Cayman Islands | 2024-02-08 | ↗ |
| 33 | Decheng Capital Global Healthcare GP, LLC | 500.0K | 0.80% | — | 500.0K | — | — | OO | Cayman Islands | 2024-02-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
88
-115 vs prev Q
New positions
29
Closed positions
137
Increased
54
Reduced
17
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 492.5K +492.5K (+100.0%) | 20.45B +20.4B (+100.0%) | 0.64% +0.642 pp | 6.03% +6.035 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 6.54M -37.8K (-0.6%) | 271.52M +6.6M (+2.5%) | 8.52% -0.106 pp | 0.00% +0.000 pp | USD38.47 +7.9% | 8 qtrs — |
| 3 | DECHENG CAPITAL LLC | 6.37M +— (+0.0%) | 264.55M +7.9M (+3.1%) | 8.30% -0.055 pp | 35.59% -9.189 pp | USD40.77 +1.8% | 8 qtrs — |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 6.00M +487.0K (+8.8%) | 249.11M +27.1M (+12.2%) | 7.82% +0.587 pp | 0.04% +0.005 pp | USD37.41 +11.0% | 8 qtrs — |
| 5 | BLACKROCK, INC. | 4.84M +256.7K (+5.6%) | 201.09M +16.3M (+8.8%) | 6.31% +0.295 pp | 0.00% +0.000 pp | USD36.03 +15.2% | 6 qtrs — |
| 6 | FMR LLC | 4.30M +432.4K (+11.2%) | 178.46M +22.7M (+14.6%) | 5.60% +0.530 pp | 0.01% +0.001 pp | USD29.38 +41.3% | 8 qtrs — |
| 7 | TCG CROSSOVER MANAGEMENT, LLC | 3.67M +— (+0.0%) | 152.39M +4.6M (+3.1%) | 4.78% -0.032 pp | 5.04% -2.229 pp | USD42.46 -2.2% | 8 qtrs — |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.44M +1.9M (+116.7%) | 142.96M +79.0M (+123.4%) | 4.49% +2.403 pp | 0.02% +0.009 pp | USD36.82 +12.8% | 8 qtrs — |
| 9 | STATE STREET CORP | 3.00M +950.0K (+46.4%) | 124.42M +42.0M (+50.9%) | 3.91% +1.221 pp | 0.00% +0.001 pp | USD36.74 +13.0% | 8 qtrs — |
| 10 | FORESITE CAPITAL MANAGEMENT VI LLC | 2.22M +— (+0.0%) | 92.24M +2.8M (+3.1%) | 2.90% -0.019 pp | 27.88% -6.687 pp | USD28.68 +44.8% | 5 qtrs — |
| 11 | RTW INVESTMENTS, LP | 2.01M +310.9K (+18.3%) | 83.54M +15.0M (+21.9%) | 2.62% +0.391 pp | 0.84% -0.008 pp | USD34.96 +18.8% | 8 qtrs — |
| 12 | UBS GROUP AG | 1.92M -202.5K (-9.5%) | 79.87M -5.8M (-6.7%) | 2.51% -0.282 pp | 0.01% -0.001 pp | USD27.01 +53.7% | 8 qtrs — |
| 13 | BRAIDWELL LP | 1.87M -1.4M (-43.0%) | 77.67M -54.6M (-41.3%) | 2.44% -1.869 pp | 2.48% -1.440 pp | USD35.26 +17.8% | 8 qtrs — |
| 14 | ALLIANCEBERNSTEIN L.P. | 1.61M -524.7K (-24.5%) | 66.99M -19.1M (-22.2%) | 2.10% -0.702 pp | 0.02% -0.006 pp | USD34.85 +19.1% | 8 qtrs — |
| 15 | FRANKLIN RESOURCES INC | 1.56M +92.3K (+6.3%) | 64.84M +5.7M (+9.6%) | 2.04% +0.108 pp | 0.02% +0.001 pp | USD37.71 +10.1% | 8 qtrs — |
| 16 | ORBIMED ADVISORS LLC | 1.52M -210.3K (-12.2%) | 62.97M -6.6M (-9.5%) | 1.98% -0.289 pp | 1.29% -0.349 pp | USD29.45 +41.0% | 6 qtrs — |
| 17 | GEODE CAPITAL MANAGEMENT, LLC | 1.51M +38.4K (+2.6%) | 62.77M +3.4M (+5.8%) | 1.97% +0.037 pp | 0.00% +0.000 pp | USD37.58 +10.5% | 8 qtrs — |
| 18 | AVIDITY PARTNERS MANAGEMENT LP | 1.47M -128.2K (-8.0%) | 61.15M -3.3M (-5.2%) | 1.92% -0.181 pp | 17.64% +2.961 pp | USD36.50 +13.8% | 8 qtrs — |
| 19 | DV TRADING LLC | 1.44M +1.4M (+100.0%) | 59.76M +59.8M (+100.0%) | 1.88% +1.876 pp | 1.68% +1.683 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 20 | PICTET ASSET MANAGEMENT HOLDING SA | 1.35M +31.0K (+2.3%) | 56.03M +2.9M (+5.5%) | 1.76% +0.029 pp | 0.05% +0.003 pp | USD27.58 +50.5% | 5 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 1.32M -42.3K (-3.1%) | 55.00M -60.0K (-0.1%) | 1.73% -0.067 pp | 0.01% +0.000 pp | USD31.47 +31.9% | 7 qtrs — |
| 22 | BANK OF AMERICA CORP /DE/ | 1.19M +441.7K (+59.0%) | 49.41M +19.3M (+63.9%) | 1.55% +0.569 pp | 0.00% +0.002 pp | USD32.39 +28.2% | 8 qtrs — |
| 23 | ACORN CAPITAL ADVISORS, LLC | 1.13M +— (+0.0%) | 46.98M +1.4M (+3.1%) | 1.47% -0.010 pp | 15.92% -7.218 pp | USD28.68 +44.8% | 5 qtrs — |
| 24 | POLAR CAPITAL HOLDINGS PLC | 1.10M +— (+0.0%) | 45.62M +1.4M (+3.1%) | 1.43% -0.009 pp | 0.18% -0.037 pp | USD38.26 +8.5% | 8 qtrs — |
| 25 | UBS ASSET MANAGEMENT AMERICAS INC | 1.09M +310.6K (+39.8%) | 45.29M +13.9M (+44.1%) | 1.42% +0.398 pp | 0.01% +0.003 pp | USD30.69 +35.3% | 7 qtrs — |
| 26 | FORESITE CAPITAL MANAGEMENT V, LLC | 1.00M +— (+0.0%) | 41.69M +1.2M (+3.1%) | 1.31% -0.009 pp | 25.36% -11.834 pp | USD37.31 +11.3% | 8 qtrs — |
| 27 | KYNAM CAPITAL MANAGEMENT, LP | 945.8K -1.1M (-52.8%) | 39.27M -41.5M (-51.4%) | 1.23% -1.398 pp | 2.51% -3.505 pp | USD34.54 +20.2% | 7 qtrs — |
| 28 | CANDRIAM S.C.A. | 797.6K -240.3K (-23.2%) | 33.12M -8.7M (-20.8%) | 1.04% -0.322 pp | 0.16% -0.054 pp | USD29.77 +39.5% | 3 qtrs — |
| 29 | ECOR1 CAPITAL, LLC | 772.0K +772.0K (+100.0%) | 32.05M +32.1M (+100.0%) | 1.01% +1.006 pp | 1.45% +1.454 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 30 | CLEARBRIDGE INVESTMENTS, LLC | 705.0K +91.2K (+14.9%) | 29.27M +4.5M (+18.4%) | 0.92% +0.114 pp | 0.02% +0.005 pp | USD40.44 +2.7% | 2 qtrs — |
| 31 | CITADEL ADVISORS LLC | 681.2K +442.4K (+185.3%) | 28.28M +18.7M (+194.1%) | 0.89% +0.575 pp | 0.00% +0.003 pp | USD38.75 +7.1% | 8 qtrs — |
| 32 | CAPTION MANAGEMENT, LLC | 602.4K +602.4K (+100.0%) | 25.01M +25.0M (+100.0%) | 0.79% +0.785 pp | 0.17% +0.172 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 33 | OCTAGON CAPITAL ADVISORS LP | 600.0K +600.0K (+100.0%) | 24.91M +24.9M (+100.0%) | 0.78% +0.782 pp | 3.02% +3.025 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 34 | JPMORGAN CHASE & CO | 586.8K +359.0K (+157.5%) | 24.37M +15.2M (+165.4%) | 0.76% +0.466 pp | 0.00% +0.001 pp | USD40.12 +3.5% | 8 qtrs — |
| 35 | MORGAN STANLEY | 545.0K -97.4K (-15.2%) | 22.63M -3.2M (-12.5%) | 0.71% -0.133 pp | 0.00% 0.000 pp | USD28.13 +47.6% | 8 qtrs — |
| 36 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 542.7K +17.2K (+3.3%) | 22.53M +1.4M (+6.4%) | 0.71% +0.018 pp | 0.00% +0.000 pp | USD38.36 +8.2% | 8 qtrs — |
| 37 | ENSIGN PEAK ADVISORS, INC | 530.8K +134.3K (+33.9%) | 22.04M +6.1M (+38.0%) | 0.69% +0.172 pp | 0.04% +0.013 pp | USD30.37 +36.7% | 7 qtrs — |
| 38 | WOODLINE PARTNERS LP | 492.5K -79.0K (-13.8%) | 20.45M -2.6M (-11.2%) | 0.64% -0.108 pp | 0.08% -0.029 pp | USD38.57 +7.6% | 8 qtrs — |
| 39 | NORTHERN TRUST CORP | 481.9K -9.4K (-1.9%) | 20.01M +219.0K (+1.1%) | 0.63% -0.017 pp | 0.00% +0.000 pp | USD37.73 +10.0% | 8 qtrs — |
| 40 | DIMENSIONAL FUND ADVISORS LP | 461.1K +8.8K (+1.9%) | 19.15M +925.5K (+5.1%) | 0.60% +0.008 pp | 0.00% +0.000 pp | USD32.17 +29.1% | 4 qtrs — |
| 41 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 426.0K -77.5K (-15.4%) | 17.69M -2.6M (-12.8%) | 0.56% -0.105 pp | 0.27% -0.024 pp | USD36.67 +13.2% | 8 qtrs — |
| 42 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 422.6K +422.6K (+100.0%) | 17.55M +17.5M (+100.0%) | 0.55% +0.551 pp | 0.01% +0.011 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 43 | OPALEYE MANAGEMENT INC. | 410.0K +— (+0.0%) | 17.02M +508.4K (+3.1%) | 0.53% -0.004 pp | 2.25% -0.089 pp | USD30.41 +36.5% | 4 qtrs — |
| 44 | SILVERARC CAPITAL MANAGEMENT, LLC | 361.2K -277.2K (-43.4%) | 15.00M -10.7M (-41.7%) | 0.47% -0.367 pp | 2.08% -1.385 pp | USD28.18 +47.3% | 3 qtrs — |
| 45 | EVENTIDE ASSET MANAGEMENT, LLC | 312.4K +312.4K (+100.0%) | 12.97M +13.0M (+100.0%) | 0.41% +0.407 pp | 0.20% +0.203 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 46 | EVERSEPT PARTNERS, LP | 308.5K +308.5K (+100.0%) | 12.81M +12.8M (+100.0%) | 0.40% +0.402 pp | 0.65% +0.645 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 47 | ROSALIND ADVISORS, INC. | 300.0K +— (+0.0%) | 12.46M +372.0K (+3.1%) | 0.39% -0.003 pp | 4.38% +0.247 pp | USD31.09 +33.5% | 3 qtrs — |
| 48 | JENNISON ASSOCIATES LLC | 282.5K +282.5K (+100.0%) | 11.73M +11.7M (+100.0%) | 0.37% +0.368 pp | 0.01% +0.007 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 49 | SCHRODER INVESTMENT MANAGEMENT GROUP | 281.1K +135.7K (+93.4%) | 11.29M +5.6M (+98.8%) | 0.37% +0.176 pp | 0.01% +0.004 pp | USD33.17 +25.2% | 4 qtrs — |
| 50 | MARSHALL WACE, LLP | 261.1K +204.7K (+363.1%) | 10.84M +8.6M (+377.4%) | 0.34% +0.266 pp | 0.01% +0.008 pp | USD41.25 +0.7% | 7 qtrs — |
| 51 | ADAR1 CAPITAL MANAGEMENT, LLC | 258.1K +9.2K (+3.7%) | 10.72M +691.6K (+6.9%) | 0.34% +0.010 pp | 0.79% -0.155 pp | USD29.67 +39.9% | 8 qtrs — |
| 52 | ARROWMARK COLORADO HOLDINGS LLC | 245.8K -11.4K (-4.4%) | 10.21M -154.3K (-1.5%) | 0.32% -0.017 pp | 0.22% +0.032 pp | USD38.21 +8.7% | 8 qtrs — |
| 53 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 242.8K +192.3K (+380.8%) | 10.08M +8.0M (+395.6%) | 0.32% +0.250 pp | 0.00% +0.001 pp | USD38.98 +6.5% | 6 qtrs — |
| 54 | AMERIPRISE FINANCIAL INC | 240.5K +132.6K (+122.8%) | 9.98M +5.6M (+129.7%) | 0.31% +0.172 pp | 0.00% +0.001 pp | USD34.96 +18.8% | 7 qtrs — |
| 55 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 201.9K -45.8K (-18.5%) | 8.38M -1.6M (-16.0%) | 0.26% -0.062 pp | 0.00% 0.000 pp | USD42.19 -1.6% | 8 qtrs — |
| 56 | LOGOS GLOBAL MANAGEMENT LP | 200.0K +200.0K (+100.0%) | 8.30M +8.3M (+100.0%) | 0.26% +0.261 pp | 0.50% +0.502 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 57 | IKARIAN CAPITAL, LLC | 199.5K -50.0K (-20.0%) | 8.28M -1.8M (-17.6%) | 0.26% -0.067 pp | 0.65% -0.368 pp | USD31.41 +32.2% | 3 qtrs — |
| 58 | BARCLAYS PLC | 187.5K +97.0K (+107.1%) | 7.79M +4.4M (+128.0%) | 0.24% +0.126 pp | 0.00% +0.001 pp | USD35.49 +17.0% | 8 qtrs — |
| 59 | TD ASSET MANAGEMENT INC | 186.4K +35.3K (+23.3%) | 7.74M +1.7M (+27.1%) | 0.24% +0.045 pp | 0.01% +0.001 pp | USD30.40 +36.6% | 7 qtrs — |
| 60 | FIRST TRUST ADVISORS LP | 181.8K +106.3K (+140.7%) | 7.55M +4.5M (+148.1%) | 0.24% +0.138 pp | 0.01% +0.003 pp | USD41.00 +1.3% | 2 qtrs — |
| 61 | SOLEUS CAPITAL MANAGEMENT, L.P. | 170.0K -120.0K (-41.4%) | 7.06M -4.6M (-39.6%) | 0.22% -0.159 pp | 0.26% -0.328 pp | USD38.73 +7.2% | 8 qtrs — |
| 62 | PFM HEALTH SCIENCES, LP | 164.0K +6.1K (+3.9%) | 6.81M +448.7K (+7.1%) | 0.21% +0.007 pp | 0.68% +0.190 pp | USD40.33 +3.0% | 2 qtrs — |
| 63 | BANK OF NEW YORK MELLON CORP | 155.2K -4.4K (-2.8%) | 6.44M +13.7K (+0.2%) | 0.20% -0.007 pp | 0.00% 0.000 pp | USD37.97 +9.3% | 8 qtrs — |
| 64 | POINT72 ASSET MANAGEMENT, L.P. | 151.4K -1.4M (-90.1%) | 6.28M -55.1M (-89.8%) | 0.20% -1.801 pp | 0.01% -0.096 pp | USD27.49 +51.0% | 8 qtrs — |
| 65 | DEUTSCHE BANK AG\ | 150.2K +77.5K (+106.6%) | 6.24M +3.3M (+112.9%) | 0.20% +0.100 pp | 0.00% +0.001 pp | USD39.61 +4.8% | 8 qtrs — |
| 66 | RUSSELL INVESTMENTS GROUP, LTD. | 143.3K +137.2K (+2,242.6%) | 5.95M +5.7M (+2,314.8%) | 0.19% +0.179 pp | 0.01% +0.006 pp | USD41.42 +0.2% | 7 qtrs — |
| 67 | NUVEEN, LLC | 134.7K -2.3K (-1.7%) | 5.59M +74.9K (+1.4%) | 0.18% -0.004 pp | 0.00% +0.000 pp | USD24.49 +69.5% | 4 qtrs — |
| 68 | LORD, ABBETT & CO. LLC | 125.6K +125.6K (+100.0%) | 5.22M +5.2M (+100.0%) | 0.16% +0.164 pp | 0.02% +0.016 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 69 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 128.5K +17.6K (+15.8%) | 5.20M +733.8K (+16.4%) | 0.17% +0.022 pp | 0.00% +0.001 pp | USD34.68 +19.7% | 8 qtrs — |
| 70 | AMERICAN CENTURY COMPANIES INC | 124.5K +32.0K (+34.6%) | 5.17M +1.4M (+38.7%) | 0.16% +0.041 pp | 0.00% +0.001 pp | USD32.84 +26.4% | 3 qtrs — |
| 71 | AQR CAPITAL MANAGEMENT LLC | 112.3K +76.0 (+0.1%) | 4.66M +142.4K (+3.1%) | 0.15% -0.001 pp | 0.00% -0.001 pp | USD25.75 +61.2% | 4 qtrs — |
| 72 | NANTAHALA CAPITAL MANAGEMENT, LLC | 109.4K +— (+0.0%) | 4.54M +135.7K (+3.1%) | 0.14% -0.001 pp | 0.15% -0.003 pp | USD40.28 +3.1% | 2 qtrs — |
| 73 | RAFFERTY ASSET MANAGEMENT, LLC | 106.1K +44.4K (+71.9%) | 4.40M +1.9M (+77.2%) | 0.14% +0.057 pp | 0.02% +0.007 pp | USD36.54 +13.6% | 7 qtrs — |
| 74 | BNP PARIBAS ARBITRAGE, SNC | 96.1K +84.4K (+723.2%) | 3.99M +3.5M (+748.5%) | 0.13% +0.110 pp | 0.00% +0.002 pp | USD39.71 +4.6% | 8 qtrs — |
| 75 | MILLENNIUM MANAGEMENT LLC | 91.5K -161.7K (-63.9%) | 3.80M -6.4M (-62.8%) | 0.12% -0.213 pp | 0.00% -0.003 pp | USD26.15 +58.8% | 8 qtrs — |
| 76 | SWISS NATIONAL BANK | 84.4K +3.1K (+3.8%) | 3.50M +229.5K (+7.0%) | 0.11% +0.003 pp | 0.00% +0.000 pp | USD30.40 +36.6% | 7 qtrs — |
| 77 | RHUMBLINE ADVISERS | 70.6K -10.2K (-12.6%) | 2.93M -321.6K (-9.9%) | 0.09% -0.014 pp | 0.00% 0.000 pp | USD37.12 +11.9% | 8 qtrs — |
| 78 | CENTERBOOK PARTNERS LP | 69.2K -326.1K (-82.5%) | 2.87M -13.1M (-82.0%) | 0.09% -0.428 pp | 0.14% -0.646 pp | USD34.02 +22.0% | 8 qtrs — |
| 79 | ALPS ADVISORS INC | 66.0K +28.5K (+76.0%) | 2.74M +1.2M (+81.5%) | 0.09% +0.037 pp | 0.02% +0.008 pp | USD35.92 +15.6% | 7 qtrs — |
| 80 | WELLS FARGO & COMPANY/MN | 62.6K +26.3K (+72.5%) | 2.60M +1.1M (+77.8%) | 0.08% +0.034 pp | 0.00% +0.000 pp | USD37.45 +10.9% | 8 qtrs — |
| 81 | BOOTHBAY FUND MANAGEMENT, LLC | 59.4K -35.1K (-37.1%) | 2.47M -1.3M (-35.2%) | 0.08% -0.047 pp | 0.04% -0.019 pp | USD31.78 +30.6% | 3 qtrs — |
| 82 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 58.1K +57.7K (+15,154.1%) | 2.41M +2.4M (+15,986.7%) | 0.08% +0.075 pp | 0.00% +0.003 pp | USD41.42 +0.2% | 3 qtrs — |
| 83 | DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN | 55.2K -8.6K (-13.4%) | 2.29M -276.8K (-10.8%) | 0.07% -0.012 pp | 0.00% 0.000 pp | USD40.28 +3.1% | 2 qtrs — |
| 84 | SECTOR GAMMA AS | 52.0K +52.0K (+100.0%) | 2.16M +2.2M (+100.0%) | 0.07% +0.068 pp | 0.49% +0.493 pp | USD41.52 +0.0% | 1 qtrs NEW |
| 85 | SUMMITTX CAPITAL, L.P. | 49.9K -36.7K (-42.4%) | 2.07M -1.4M (-40.6%) | 0.07% -0.049 pp | 0.06% -0.082 pp | USD35.31 +17.6% | 4 qtrs — |
| 86 | LEGAL & GENERAL GROUP PLC | 45.1K +1.9K (+4.4%) | 1.87M +132.9K (+7.6%) | 0.06% +0.002 pp | 0.00% +0.000 pp | USD30.82 +34.7% | 8 qtrs — |
| 87 | VOYA INVESTMENT MANAGEMENT LLC | 43.7K -4.3K (-8.9%) | 1.82M -117.6K (-6.1%) | 0.06% -0.006 pp | 0.00% 0.000 pp | USD39.79 +4.3% | 8 qtrs — |
| 88 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 43.1K +3.2K (+8.0%) | 1.78M +178.1K (+11.1%) | 0.06% +0.004 pp | 0.00% +0.000 pp | USD32.49 +27.8% | 7 qtrs — |
| 89 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 41.7K +2.9K (+7.4%) | 1.73M +167.9K (+10.8%) | 0.05% +0.003 pp | 0.00% +0.000 pp | USD31.45 +32.0% | 8 qtrs — |
| 90 | AMI ASSET MANAGEMENT CORP | 41.2K -2.9K (-6.6%) | 1.71M -66.2K (-3.7%) | 0.05% -0.004 pp | 0.10% -0.002 pp | USD27.83 +49.2% | 3 qtrs — |
| 91 | JANE STREET GROUP, LLC | 40.7K +27.0K (+197.1%) | 1.69M +1.1M (+206.2%) | 0.05% +0.035 pp | 0.00% +0.000 pp | USD41.10 +1.0% | 2 qtrs — |
| 92 | PDT PARTNERS, LLC | 40.0K +— (+0.0%) | 1.66M +49.6K (+3.1%) | 0.05% 0.000 pp | 0.11% +0.006 pp | USD24.58 +68.9% | 4 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
594.2K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+594,164
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Mulay James | Director | M-Exempt | A | Common Stock | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2026-04-15 | Patterson Joshua F. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 45,266 | 67.68 | 3.06M | 45,266 | D | ↗ |
| 2026-04-15 | Kuan Arthur | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 271,600 | 67.68 | 18.38M | 271,600 | D | ↗ |
| 2026-04-15 | Kasturi Vijay | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 79,216 | 67.68 | 5.36M | 79,216 | D | ↗ |
| 2026-04-15 | DETORE JAMES M. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 90,574 | 67.68 | 6.13M | 90,574 | D | ↗ |
| 2026-04-15 | Bellete Ambaw | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 107,508 | 67.68 | 7.28M | 107,508 | D | ↗ |
| 2026-03-16 | Mulay James | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,310 | 12.59 | 16.5K | 3,930 | D | ↗ |
| 2026-03-12 | Kuan Arthur | Director / Officer | F-InKind | D | Common Stock | 1,847 | 60.15 | 111.1K | 198,916 | D | ↗ |
| 2026-03-04 | Kuan Arthur | Director / Officer | M-Exempt | A | Common Stock | 102,871 | 1.72 | 176.9K | 139,022 | D | ↗ |
| 2026-01-09 | Mulay James | Director | M-Exempt | D | Director Stock Option (right to buy) | 654 | 3.72 | 2.4K | 1,308 | D | ↗ |
| 2025-11-24 | Rossi Christina | Director | A-Award | A | Director Stock Option (right to buy) | 20,889 | 43.56 | 909.9K | 20,889 | D | ↗ |
| 2025-11-17 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,000 | 0.60 | 600.00 | 117,077 | D | ↗ |
| 2025-11-17 | DETORE JAMES M. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-10-13 | POST LEONARD E | Director | M-Exempt | A | Common Stock | 1,000 | 0.60 | 600.00 | 1,000 | D | ↗ |
| 2025-10-09 | Mulay James | Director | M-Exempt | D | Director Stock Option (right to buy) | 5,903 | 3.72 | 22.0K | 1,962 | D | ↗ |
| 2025-09-30 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 5,000 | 0.60 | 3.0K | 119,077 | D | ↗ |
| 2025-09-29 | Mulay James | Director | M-Exempt | A | Common Stock | 12,755 | 1.82 | 23.2K | 12,755 | D | ↗ |
| 2025-09-19 | Mulay James | Director | S-Sale | D | Common Stock | 3,574 | 38.99 | 139.4K | 0 | D | ↗ |
| 2025-09-18 | Mulay James | Director | M-Exempt | D | Director Stock Option (right to buy) | 19,112 | 1.82 | 34.8K | 16,329 | D | ↗ |
| 2025-09-15 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,000 | 0.60 | 600.00 | 124,077 | D | ↗ |
| 2025-09-11 | Liu Brian Guan-Chyun | Director | P-Purchase | A | Common Stock | 1,515,151 | 33.00 | 50.00M | 1,515,151 | I | ↗ |
| 2025-09-05 | Mulay James | Director | M-Exempt | A | Common Stock | 27,015 | 0.60 | 16.2K | 27,015 | D | ↗ |
| 2025-09-03 | Song Hong Fang | Director | S-Sale | D | Common Stock | 100 | 28.96 | 2.9K | 2,904,031 | I | ↗ |
| 2025-09-03 | POST LEONARD E | Director | M-Exempt | A | Common Stock | 1,000 | 0.60 | 600.00 | 1,000 | D | ↗ |
| 2025-08-05 | Lapetina Bob | Officer | — | — | Employee Stock Option (Right to Buy) | 21,586 | 20.11 | 434.1K | 0 | D | ↗ |
| 2025-07-17 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 2,000 | 0.60 | 1.2K | 126,077 | D | ↗ |
| 2025-06-05 | Tong Victor Edward Jr | Director | A-Award | D | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-06-05 | Song Hong Fang | Director | A-Award | A | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-06-05 | POST LEONARD E | Director | A-Award | A | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-06-05 | Mulay James | Director | A-Award | A | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-06-05 | Liu Brian Guan-Chyun | Director | A-Award | A | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-06-05 | Graf Susan E | Director | A-Award | A | Director Stock Option (right to buy) | 24,165 | 26.63 | 643.5K | 24,165 | D | ↗ |
| 2025-05-21 | POST LEONARD E | Director | M-Exempt | A | Common Stock | 1,000 | 0.60 | 600.00 | 1,000 | D | ↗ |
| 2025-04-28 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,000 | 0.60 | 600.00 | 129,077 | D | ↗ |
| 2025-04-15 | Roche Corleen M. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 143,907 | 20.11 | 2.89M | 143,907 | D | ↗ |
| 2025-04-15 | Patterson Joshua F. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 119,922 | 20.11 | 2.41M | 119,922 | D | ↗ |
| 2025-04-15 | Kuan Arthur | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 527,660 | 20.11 | 10.61M | 527,660 | D | ↗ |
| 2025-04-15 | Kasturi Vijay | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 203,868 | 20.11 | 4.10M | 203,868 | D | ↗ |
| 2025-04-15 | Bellete Ambaw | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 284,816 | 20.11 | 5.73M | 284,816 | D | ↗ |
| 2025-03-17 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,000 | 0.60 | 600.00 | 130,077 | D | ↗ |
| 2025-02-18 | POST LEONARD E | Director | M-Exempt | D | Director Stock Option (right to buy) | 1,000 | 0.60 | 600.00 | 131,077 | D | ↗ |
| 2025-01-13 | POST LEONARD E | Director | M-Exempt | A | Common Stock | 1,000 | 0.60 | 600.00 | 1,000 | D | ↗ |
| 2024-12-16 | Song Hong Fang | Director | S-Sale | D | Common Stock | 700,000 | 28.00 | 19.60M | 3,003,931 | I | ↗ |
| 2024-12-16 | POST LEONARD E | Director | M-Exempt | D | Stock Option | 1,000 | 0.60 | 600.00 | 133,077 | D | ↗ |
| 2024-12-06 | POST LEONARD E | Director | M-Exempt | D | Stock Option | 1,000 | 0.60 | 600.00 | 134,077 | D | ↗ |
| 2024-10-04 | Tong Victor Edward Jr | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Song Hong Fang | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Roche Corleen M. | Officer | A-Award | A | Stock Option (Right to Buy) | 93,600 | 36.63 | 3.43M | 93,600 | D | ↗ |
| 2024-10-04 | Patterson Joshua F. | Officer | A-Award | A | Stock Option (Right to Buy) | 47,775 | 36.63 | 1.75M | 47,775 | D | ↗ |
| 2024-10-04 | POST LEONARD E | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Mulay James | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Liu Brian Guan-Chyun | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Kuan Arthur | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 397,800 | 36.63 | 14.57M | 397,800 | D | ↗ |
| 2024-10-04 | Kasturi Vijay | Officer | A-Award | A | Stock Option (Right to Buy) | 132,600 | 36.63 | 4.86M | 132,600 | D | ↗ |
| 2024-10-04 | Graf Susan E | Director | A-Award | A | Stock Option (Right to Buy) | 15,600 | 36.63 | 571.4K | 15,600 | D | ↗ |
| 2024-10-04 | Bellete Ambaw | Officer | A-Award | A | Stock Option (Right to Buy) | 175,500 | 36.63 | 6.43M | 175,500 | D | ↗ |
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | C-Conversion | A | Common Stock | 3,628,198 | 0.00 | — | 4,558,812 | — | ↗ |
| 2024-01-24 | Mulay James | Director | — | D | Stock Option | 7,865 | 3.72 | 29.3K | 0 | — | ↗ |
| 2024-01-24 | Graf Susan E | Director | — | D | Stock Option | 104,876 | 7.82 | 820.1K | 0 | — | ↗ |
| 2024-01-24 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 930,612 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-11.3K
Shares Outstanding
84.44M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Arthur Kuan, Chief Executive Officer | 690.0K | — | 3.45M | 7.35M | 414.0K | 22.0K | 11.93M | 90.56% | ↗ |
| 2 | 2025 | Ambaw Bellete, President and Chief Operating Officer | 537.9K | — | — | 3.97M | 269.0K | 40.9K | 4.82M | 82.39% | ↗ |
| 3 | 2025 | Vijay Kasturi, Chief Medical Officer | 502.9K | — | — | 2.84M | 226.3K | 30.7K | 3.60M | 78.89% | ↗ |
| 4 | 2025 | Joshua F. Patterson, General Counsel, Chief Compliance Officer, and Secretary | 461.5K | — | — | 1.67M | 207.7K | 24.6K | 2.36M | 70.66% | ↗ |
| 5 | 2025 | Corleen Roche, Prior Chief Financial Officer | 288.9K | — | — | 2.00M | — | 28.7K | 2.32M | 86.32% | ↗ |
| 6 | 2025 | Robert Lapetina (Prior Interim Principal Financial and Accounting Officer) | 310.2K | 2.3K | — | 300.7K | — | 32.1K | 645.3K | 46.60% | ↗ |
| 7 | 2025 | Jim DeTore, Chief Financial Officer | 96.0K | — | — | — | — | — | 96.0K | 0.00% | ↗ |
| 8 | 2024 | Arthur Kuan, Chief Executive Officer | 653.5K | — | — | 10.14M | 382.6K | 1.5K | 11.17M | 90.71% | ↗ |
| 9 | 2024 | Corleen Roche, Prior Chief Financial Officer | 446.4K | 31.5K | — | 9.16M | 196.4K | 13.6K | 9.85M | 93.01% | ↗ |
| 10 | 2024 | Corleen Roche, Chief Financial Officer | 446.4K | 31.5K | — | 9.16M | 196.4K | 13.6K | 9.85M | 93.01% | ↗ |
| 11 | 2024 | Ambaw Bellete, President and Chief Operating Officer | 511.9K | — | — | 4.47M | 243.0K | 15.0K | 5.24M | 85.31% | ↗ |
| 12 | 2023 | Arthur Kuan, Chief Executive Officer | 449.0K | — | — | 3.29M | 189.0K | 3.0K | 3.93M | 83.71% | ↗ |
| 13 | 2023 | Ambaw Bellete, President and Chief Operating Officer | 322.0K | 189.5K | — | 1.97M | 180.6K | 370.0K | 3.03M | 64.94% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arthur Kuan | Chairman & Chief Executive Officer | 1M | male |
| Ambaw Bellete | President & Chief Operating Officer | 847.8K | male |
| James DeTore | Chief Financial Officer | 785.5K | male |
| Vijay Kasturi | Chief Medical Officer | 760.0K | — |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | 693.8K | male |
| Bing Kung | Vice President of Corporate Development | — | male |
| Amy Steele | Vice President of Finance & Administration | — | female |
| Sarah Connors | Vice President of Communications & Patient Advocacy | — | female |
| Swapnil Bhargava | Chief Technical Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CGON
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
